JUN 09, 2021 4:12 PM PDT

New Drug Prevents Dementia After Head Injury

WRITTEN BY: Annie Lennon

Researchers led by the University of South Australia have identified a new drug that may be able to help prevent athletes from developing dementia following repeated head injuries. 

Chronic traumatic encephalopathy (CTE) is a progressive and fatal brain disease linked to the accumulation of a protein known as hyperphosphorylated tau. The build-up of this protein in the brain affects cognition and behavior. The condition is a form of head injury-associated dementia. 

As a rationale for the development of the new drug, the researchers say that after a head injury, the brain releases a neurotransmitter called substance P. This neurotransmitter is known to modulate pain perception. It also plays a role in the secondary injury process after traumatic brain injury, particularly in neuroinflammation, increased blood-brain barrier permeability and edema formation, which has been linked to increased intracranial pressure. 

In the case of CTE, substance P has also been linked to increased amounts of tau protein that collect inside neurons. This build-up leads to memory problems, confusion, changes in personality, aggressive behavior, depressive mood and suicidal thoughts. 

For the current study, the researchers used a drug known as a Neurokinin-1 (NK-1) receptor antagonist to block substance P in animal models of CTE. In doing so, they were able to prevent tau protein tangles from developing in the brain and leading to neurological problems. 

The researchers now hope that CTE could be prevented via the same mechanism in humans. Bob Vink, the lead author of the study, now hopes to progress the treatment into human clinical trials, where it may be able to aid athletes who play contact sports including boxers and footballers, as well as military veterans who sustain head injuries during conflict. He said however that this may take several years as currently, CTE can only be diagnosed post-mortem. 

 

Sources: University of South AustraliaScientific Reports 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
AUG 03, 2021
Drug Discovery & Development
A pediatric-friendly drug to combat snail fever
AUG 03, 2021
A pediatric-friendly drug to combat snail fever
           Schistosomiasis, also known as Bilharzia or snail fever, is a disease  ...
AUG 12, 2021
Cancer
Promising Drug Target Identified for Deadly Ovarian Cancer
AUG 12, 2021
Promising Drug Target Identified for Deadly Ovarian Cancer
Scientists at the University of Alabama at Birmingham have identified a gene called DOT1L for its role in progressing th ...
AUG 15, 2021
Drug Discovery & Development
Diabetes Drug May Reduce Alzheimer's Risk
AUG 15, 2021
Diabetes Drug May Reduce Alzheimer's Risk
People who take a drug used to lower blood sugar levels in type 2 diabetes have less amyloid-beta in their brains, a bio ...
SEP 07, 2021
Neuroscience
Researchers Harness the Power of Machine Learning to Facilitate Drug Repurposing
SEP 07, 2021
Researchers Harness the Power of Machine Learning to Facilitate Drug Repurposing
Using machine learning and massive data sets from patients, researchers identify drug and drug combinations that could b ...
SEP 09, 2021
Drug Discovery & Development
Can vaccines help prevent and treat opioid addiction?
SEP 09, 2021
Can vaccines help prevent and treat opioid addiction?
According to the United States Centers for Disease Control (CDC), 136 people die from an opioid overdose every ...
OCT 01, 2021
Technology
SnapTec® - Single-handed operation for fast and safe sample handling
OCT 01, 2021
SnapTec® - Single-handed operation for fast and safe sample handling
The new Eppendorf Conical Tube SnapTec 50 offers all the advantages of classic conical tubes 50 mL. The decisive, innova ...
Loading Comments...